Avenue Therapeutics Announces High Potency And Full Efficacy In A Model Of Generalized Seizures For Its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
Portfolio Pulse from Happy Mohamed
Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced that its drug BAER-101 significantly suppressed seizures in a preclinical animal model of absence epilepsy. The drug demonstrated full suppression of seizure activity with a minimal effective dose. BAER-101 has previously been shown to be safe with minimal side effects in clinical studies by AstraZeneca. The company plans to initiate a Phase 2a study in 2024.
August 01, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avenue Therapeutics' BAER-101 shows promising results in preclinical epilepsy model, which could lead to a Phase 2a study in 2024. This could potentially boost the company's stock in the short term.
The positive preclinical results for BAER-101, a drug developed by Avenue Therapeutics, could potentially lead to a Phase 2a study in 2024. This development is likely to generate positive sentiment among investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100